

Case Report

Open Access

Two Stage Hepatopancreatectomy on Frantz Tumor: A Case Report

Magana Mainero Pablo^{1,2,4}, Hernandez Luna Valeria^{4,5*}, Afya Avi¹, Dominguez Rosado Ismael^{2,3} and Chan Nunez Luis Carlos^{2,3}

¹General Surgery, ABC Medical Center, Mexico City, Mexico

²Liver-Pancreatic-Biliary Surgery, Mexico

³National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico

⁴Angels Hospital, South Central, Queretaro, Mexico

⁵Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

ABSTRACT

The solid pseudopapillary pancreatic tumor also called “Frantz tumor”, first described in 1959 by Dr. Frantz Gruber. Part of the classification of cystic neoplasms of the pancreas, it is a condition presented predominantly in young women up to in 90% of cases.

A 24-year-old female patient, with abdominal pain of 3 days, accompanied by nausea, vomiting and abdominal distention. A tomography was performed that identified a lesion with a solid aspect of the pancreatic parenchyma at the level of the tail, in the liver lesions in segments VIII and V. A subtotal pancreatectomy was performed with splenectomy, with biopsy of liver lesions, reporting positive for malignancy. It was decided to perform a right portal vein ligation. In the eight postoperative day, right two staged hepatectomy was completed.

In the postoperative day one of the second surgery, she presented clinical sings compatible with bleeding, it was confirmed with tomography as a hematoma in the surgical bed. Exploratory laparotomy was performed with hematoma drainage. She went to an Intensive Care Unit, where she further evolved without complications.

Postoperative bleeding in patients with hepatectomy varies from 4.2% to 10%, and the reasons described for which it occurs are several. In our case, in relation to bleeding on the surface of the resection, diagnosis and control were accurately performed.

Surgical postoperative bleeding is one of the most frequent operative complications of hepatectomy, so it is necessary to keep it in mind and not prolong its treatment for definitive control.

*Corresponding author

Valeria Hernandez Luna, Hospital Angeles Centro Sur. Bernardo Quintana Arrijoa Boulevard 9670, Centro Sur, Zip Code 76090, Santiago de Querétaro, Querétaro, Mexico & Faculty of Medicine, National Autonomous University of Mexico (UNAM). Circuito Interior s/n, University City, Coyoacan, Zip Code 04510, Mexico City, Mexico.

Received: September 02, 2025; **Accepted:** September 04, 2025; **Published:** January 28, 2026

Keywords: Pancreatic Neoplasm, Solid Pseudopapillary Tumor of Pancreas, Portal Vein Ligation, Hepatectomy

Abbreviations

SPT: Solid Pseudopapillary Tumor of the Pancreas

WHO: World Health Organization

FRL: Future Remnant Liver

PVL: Portal Vein Ligation

ALPPS: Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy

PET: Positron Emission Tomography

CT: Computed Tomography

Introduction

The solid pseudopapillary tumor of the pancreas (SPT) also called

“Frantz’s tumor” was first described in 1959 by Dr. Frantz Gruber, however, it was in 1970 when Hamoudi described the histopathology and until 1980 that Kloppel described it as a particular clinical entity. In 1996 the World Health Organization (WHO) defined it as “Pseudopapillary solid neoplasm” [1].

This tumor belongs to the classification of pancreatic cystic neoplasms, being the least common, with an incidence of 1-3% among them. It predominantly affects young women in 90% of cases, with a mean age of 22 years (range: 20-30 years), although it has also been reported in men (mean age: 37 years) and children (under 12 years old) [1,2]. The average size ranges from 6 to 8 cm, but some cases reach diameters of 15 to 22 cm [3]. Furthermore, although it presents a low risk of malignancy, up to 15% of patients may develop metastases [4]. SPT has been associated with mutations

in exon 3 of CTNNB1 and alterations in Wnt/B-catenin and Hedgehog signaling pathways [3].

In this context, the ALPPS technique (Associating Liver Partition and Portal vein Ligation for Staged Hepatectomy) first described in 2012, is designed to rapidly increase the volume of the future remnant liver (FRL), allows liver resections in two stages. It combines two established procedures: right portal vein ligation (PVL), which restricts blood flow to a portion of the liver, and in situ liver splitting, which allows for enhanced regeneration of the organ to facilitate resection of the remaining portion [5,6].

ALPPS-induced liver regeneration is mainly attributed to portal hemodynamic alterations rather than to circulating proliferative factors. Hepatic transection and portal ligation generate an increase in portal flow in the FLR, which increases portal pressure and stimulates hepatocyte hypertrophy, reaching a growth of 65% to 110% in an interval of 6 to 15 days. This process involves the activation of signaling pathways such as JNK1-IHH, the production of nitric oxide by the sinusoidal endothelium and the induction of hypoxia in the FLR, which enhances cell proliferation. In experimental models, an increase of 60% in 24 hours and up to 134% in 72 hours has been reported. In addition, hepatic transection disrupts porto-portal collaterals, preventing venous outflow leakage and ensuring a more effective regenerative stimulus. These findings suggest that regeneration in ALPPS is predominantly driven by changes in hepatic hemodynamics and sinusoidal microcirculation, rather than by cytokines or growth factors [7].

ALPPS has been used mainly in patients with bilobar liver metastases or primary liver tumors initially considered unresectable, achieving success rates close to 99% in the second stage [5].

On the other hand, there are different types of ALPPS that are applied according to the clinical situation of the patient, including Classic ALPPS, which involves complete transection of the hepatic parenchyma and ligation of the portal vein, and Partial ALPPS, with partial transection of the parenchyma and ligation of the portal vein. Mini ALPPS is characterized by partial parenchymal transection and portal vein embolization through the inferior mesenteric vein. In addition, Hybrid ALPPS combines complete transection with an anterior approach and two-stage portal embolization. Finally, Modified ALPPS preserves the portal pedicles during liver transection [5].

The accelerated hepatic regeneration promoted by the ALPPS technique allows complete resection in a shorter period of time, usually between 7 and 15 days between surgical stages; however, this technique also entails an increase in postoperative morbidity [5].

We are dealing with an infrequent entity with an even rarer presentation, so we consider it important to present the case and a review of the subject with the complications associated with surgical treatment.

Case Presentation

24-year-old female patient, with a history of peptic acid disease of 2 years of evolution under control with medical treatment and irritable bowel syndrome under control. She started her symptoms with abdominal pain of 3 days of evolution, of transictal type in the epigastrium of intensity 7/10, accompanied by nausea, vomiting and abdominal distension. On physical examination there were no specific findings, the initial laboratories were within normal parameters, so imaging studies were performed.

Double contrast tomography identified a solid-cystic lesion of the pancreatic parenchyma at the level of the tail with dimensions of 62 x 75 x 70 mm. In addition, in the liver there were lesions in segment VIII of 13 mm and segment V of 16 and 12 mm (Figure 1).



Figure 1: Double contrast CT-Scan identified a solid-cystic lesion on the pancreatic parenchyma at tail's level with the following dimensions 62 x 75 x 70 mm, with heterogeneous reinforcement and mass effect towards the greater curvature of the stomach and involvement of splenic arterial and venous branches with data of engorgement and collateralization of its branches. In addition, the liver showed solid hypodense lesions with diffuse heterogeneous reinforcement during the contrasted phases suggestive of secondary deposits; in segment VIII of 13 mm and segment V of 16 mm and 12 mm

The patient was admitted to complete the study protocol, PET CT was requested and reported: lesion in the tail of the pancreas, of heterogeneous density, solid, with lobulated and well-defined border, measuring 67 x 83 mm in its major axes, associated with metabolism with a maximum SUV of 14.5. The liver with multiple hypodense lesions in segments V, VI, VII and VIII, the largest lesion in segment 6, measuring 17 mm, and associated with increased metabolism with maximum SUV of 7.1, with splenomegaly (Figure 2). Tumor markers were requested, which were reported in normal ranges; Carcino Embryonic Antigen of 5, Alpha-feto protein of 1.1, Ca 19.9 of 2. Subsequently, an endoscopic ultrasound biopsy was performed, which reported a solid pseudopapillary tumor of the pancreas (TSP), so it was scheduled for surgery.




Figure 2: The liver presented multiple hypodensity lesions in segments V, VI, VII and VIII, the largest lesion on segment VI with 17 mm, associated with an increased metabolism with a maximum SUV of 7.1 and splenomegaly. No mesenteric, retroperitoneal adenopathies, iliac chains or inguinal were identified

He was scheduled for subtotal pancreatectomy with splenectomy (Figure 3), biopsy of hepatic lesions in segments IV, VI, VII reported positive for malignancy so it was also decided to perform ligation of the right portal vein. Without complications.



Figure 3: Product of the Distal Pancreatectomy with Splenectomy

The pathology reported: Pancreas; solid pseudopapillary carcinoma without neoplasia in surgical edge. Liver biopsy; solid pseudopapillary carcinoma metastatic in two hepatic wedges.

On the 8th postoperative day a right hepatectomy was performed on a scheduled basis, within the transoperative findings were reported; Hypertrophy of the left hepatic lobe with metastasis of pseudopapillary carcinoma of the pancreas limited to the right liver, without evidence of invasion by transoperative ultrasound.

On the first postoperative day of the second procedure, he presented with hemorrhage data that was confirmed by tomography (Figure 4) as a hematoma in the surgical site. He underwent exploratory laparotomy in which a 1300 ml hematoma drainage and hemostasis of the surgical site was performed. He was transferred to the Intensive Care Unit due to the history of hemorrhage and for close monitoring, he evolved without complications and was discharged on the ninth postoperative day, without other incidents.



Figure 4: Extensive hematoma is observed in surgical bed, it extends from the subphrenic region to the flank, with approximate dimension of 20 x 9 x 7.8 cm, with a 730cc estimated volumen. The hematoma has heterogeneous density ranging from 20 to 66 HU, in relation to different stages of bleeding

Discussion

Solid pseudopapillary tumor of the pancreas is a rare tumor and requires surgery for its treatment. Among its frequent postoperative complications are biochemical leakage and pancreatic fistula, peripancreatic collections and abscesses, hemorrhage and hematoma, pancreatic pseudocyst, intestinal occlusion, cholangitis and surgical wound infection [8]. Postoperative bleeding in hepatectomy patients ranges from 4.2-10%, and the described reasons for its occurrence are threefold: 1) bleeding from the resection surface, 2) incomplete hemostasis in the transoperative period, and 3) loss of tension or release of vascular staples or sutures [9,10].

In this case, the hemorrhage was related to the first cause described, was diagnosed and optimally controlled. It is increasingly feasible to diagnose and treat these tumors at a wider range of stages, however, complications arising from pancreatic and hepatic resections represent a significant challenge for the surgeon and the medical team. The morbidity and mortality of these patients can increase rapidly, so these procedures should be performed in specialized centers by a multidisciplinary team with experience in the management of these complications.

Hepatopancreatectomies are highly complex procedures that require meticulous surgical planning. In this case, in order to optimize the hypertrophy of the future remnant liver (FLR) and to allow a safe two-stage resection, we chose to perform a Mini-ALPPS, a modified variant of the classic ALPPS. Unlike the latter, where hepatic transection is complete in the first stage, Mini-ALPPS employs partial parenchymal transection and portal vein embolization to stimulate hepatic hypertrophy in a more controlled manner, avoiding extensive manipulation of the hepatic hilum and reducing the physiological impact of the procedure [11].

In previous studies, it has been shown that liver regeneration in Mini-ALPPS occurs mainly due to hemodynamic changes that increase portal flow to the FLR, favoring a more rapid hypertrophy than that observed in conventional techniques such as portal embolization [11]. However, although Mini-ALPPS allows accelerated liver regeneration, it has also been reported that it may be associated with higher postoperative morbidity and mortality compared to less invasive techniques, particularly in patients with advanced liver fibrosis [11].

In comparison with other reports of Mini-ALPPS, in this case we were able to complete the resection in two times with adequate FLR growth and without major postoperative complications. These findings reinforce the usefulness of this technique in patients with liver metastases from pancreatic tumors, in whom the remaining liver volume may be a limiting factor for complete oncologic resection [11].

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this case report.

Conclusion

Frantz tumor is a rare entity, with greater frequency in young women, surgery persists as the therapeutic option of choice, being the resection with free margins, routine lymphadenectomy has not proven to be useful.

Metastases of this tumor are present in 20% of the cases at the time of diagnosis and the cases in which a resection of these metastases can be performed in the same surgical time are exceptional [12].

The complications we face peri-operatively due to resection of the primary tumor in the pancreas or metastases in the liver are not negligible in frequency and have a direct effect on the patient's prognosis [13-15].

References

1. Dinarvand P, Lai J (2017) Solid pseudopapillary neoplasm of the pancreas: A rare entity with unique features. *Arch Pathol Lab Med* 141: 990-995.
2. Fasanella KE, McGrath K (2009) Cystic lesions and intraductal neoplasms of the pancreas. *Best Pract Res Clin Gastroenterol* 23: 35-48.
3. Zalatnai A, Kis Orha V (2020) Solid pseudopapillary neoplasms of the pancreas is still an enigma: A clinicopathological review. *Pathol Oncol Res* 26: 641-649.
4. Printes TRM, De Castro GL, Rabelo DC, Da Silva Neto RA, Da Silva Junior RA (2024) Frantz's tumor as incidental finding during Heller myotomy for achalasia: Case report and review of literature. *Ann Med Surg (Lond)* 86: 4861-4864.
5. Memeo R, Conticchio M, Deshayes E, Nadalin S, Herrero A, et al. (2021) Optimization of the future remnant liver: Review of the current strategies in Europe. *Hepatobiliary Surg Nutr* 10: 350-363.
6. Balci D, Sakamoto Y, Li J, Di Benedetto F, Kırımker EO, et al. (2020) Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure for cholangiocarcinoma. *Int J Surg* 82: 97-102.
7. Zhang S, Ma Y, Chen X, Wu S, Chen G (2025) Circulating proliferative factors versus portal inflow redistribution: Mechanistic insights of ALPPS-derived rapid liver regeneration. *Front Oncol* 14: 1429564.
8. Romics L, Olah A, Belagyi T, Hajdu N, Gyurus P, et al. (2010) Solid pseudopapillary neoplasm of the pancreas proposed algorithms for diagnosis and surgical treatment. *Langenbecks Arch Surg* 395: 747-755.
9. Jin S, Fu Q, Wuyun G, Wuyun T (2013) Management of post-hepatectomy complications. *World J Gastroenterol* 19: 7983-7991.
10. Russell MC (2015) Complications following hepatectomy. *Surg Oncol Clin N Am* 24: 73-96.
11. Liu GM, Zhang YM (2023) Mini ALPPS based multidisciplinary treatment leading to long-term survival in a patient with a large HCC: A case report. *Front Surg* 9: 920953.
12. Reddy S, Cameron JL, Scudiere J, Hruban RH, Fishman EK, et al. (2009) Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): A large single-institutional series. *J Am Coll Surg* 208: 950-957.
13. Eshmuminov D, Raptis DA, Linecker M, Wirsching A, Lesurtel M, et al. (2016) Meta analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy. *Br J Surg* 103: 1768-1782.
14. Lang H, Baumgart J, Mittler J (2020) Associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) registry: What have we learned? *Gut Liver* 14: 699-706.
15. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, et al. (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. *Ann Surg* 255: 405-414.

Copyright: ©2026 Hernandez Luna Valeria, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.